- Email: [email protected]
Subject index volume 47
SUBJECT INDEX Volume 47 January
- June 1993
Anordiol, synthesis of derivatives, 507 Anordrin + RU 486, 317, 597 Anordrin/anordiol + RU 486, 413, 619 Antifertility effect, human seminal plasma inhibin immunization, 491 tamoxifen, 307 Antioxidant erythrocyte enzyme activities, OC use, 591 Bacille Calmette Guerin, intravasal application, 303 Barrier efficacy, condoms, 559 Biphasic OC, 55, 69 Bleeding patterns, 3-ketodesogestrel, 251 nomegestrol acetate, 97 triphasic OCs, 43 Blood loss, termination of pregnancy, a5 Blood pressure, monophasic OCs, 367 Breast cancer and OC use, 241 Breast cancer prevention, prototype contraceptive, 427 Carbohydrate metabolism, biphasic OC, 55 Cells adherent to IUDs, 205 Chemical male sterilization, 107 Condom choice for contraception, 539 Contraception, older women, 229 Contraceptive choice determinants, 539 Contraceptive potential, tamoxifen, 307 Copper IUDs, 37 Copper release, Cu IUDs, 349 CUT-200, 349, 483 Depot-medroxyprogesterone acetate, 177, 445 Derivatives synthesis, anordiol, 507 Determinants of contraceptive choice, 539 Efficacy, POCs, 1 Endometrial suction, 469 Endometrial trace elements, IUDs, 483 Epididymal injection, zinc arginine, 107 Epostane + RU 486, 499 Erythrocyte enzyme activities, OC use, 591 Ethinyl estradiol + desogestrel, 55, 69, 229, 263, 367, 591 Ethinyl estradiol + gestodene, 263, 367, 583 Ethinyl estradiol + levonorgestrel, 43, 367, 421, 515 Ethinyl estradiol + norethindrone, 43, 131 Ethinyl estradiol + norethisterone acetate, 367, 421 Ethinyl estradiol + norgestrel, 131, 445 Ethinyl estradiol, metabolism, 263 pharmacokinetics, 263 Gemeprost + mefipristone, 75 Genotoxic effect, gossypol acetic acid, 385 Gonadotropin hormone agonist + replacement hormones, 427
620
Contraception
Gossypol acetic acid, genotoxic effect, 385 Gyne T 380, 37 Hormonal parameters, biphasic OC, 55 Human seminal plasma inhibin immunization, 491 :~~~~~~~~fo:r-k~~~~~e~~~~~~~e~~a~~~,i:~:bin, 491 Injectable
contraceptive, depot-medroxyprogesterone acetate, 177, 445 Intrauterine device (IUD), CUT-200, 349, 483 Gyne T 380, 37 levonorgestrel-releasing, 169, 325 Lippes loop, 483 Multiload-375, 325 Nova-T, 325, 349 TCu-380A (Ag), 325 Intravasal Bacille Calmette Guerin, 303 IUD (intrauterine device) IUD choice for contraception, 539 IUD use, safety monitor, 359 IUDs, tumor necrosis factor alpha, 205 3-Keto-desogestrel, subdermal implant, 215, 251 Lactating women, POC use, 23 Latex condoms, barrier efficacy, 559 Levonorgestrel, menstrual blood loss, 455 subdermal implant, 149, 193, 569 Levonorgestrel IUD, 169, 325 Lipid metabolism, biphasic OC, 69 depot-medroxyprogesterone acetate, 177, 445 ethinylestradiol + norgestrel, 445 levonorgestrel, 149 triphasic OCs, 131 Lipid peroxidation, OCs, 421 Lippes loop, 483 Lupron DepotR + Premarin R + Provera R , 427 Male antifertility compounds, Triptergium wilfordii, 387 Male fertility control, 303 Male sterilization, 197 Mechanism of action, POCs, 1 Mefipristone + gemeprost, 85 Mefipristone + sulprostone, 123 Menstrual blood loss, levonorgestrel, 455 Misoprostol + RU 486, 295 Mollugo pentaphylla, spermicidal activity, 401 Monitor, safety of IUD use, 359 Monophasic OCs, 367 Multiload-375, 325 Multiple sclerosis incidence, OC use, 161 reproductive factors, 161 Nomegestrol acetate, subdermal implant, 97 Non-hormonal contraception, endometrial suction, 469
Contraception Norethisterone, 527 Norgestimate, metabolism, 283 receptor binding, 283 Norgestrel POC, 23 Norgestr 1 use, lactating women, 23 Norplant fi, 149, 193, 569 Nova-T, 325, 349 OC use, multiple sclerosis incidence, 161 OC use and breast cancer, 241 OCs (oral contraceptives) Older women, contraception, 229 Ovarian activity, 3-ketodesogestrel, 251 ultrasound, 583 Ovarian function, norethisterone, 527 Performance, levonorgestrel-releasing IUD, 169 Pharmacokinetics, ethinyl estradiol, 263 Pill choice for contraception, 539 Pill-free interval, blood pressure, 367 POC use, lactating women, 23 POCs (progestogen-only contraceptives) Postcoital non-hormonal contraception, 469 Postcoital use, anordrin/anordiol + RU 486, 413 Pregnancy termination, RU 486 + anordrin, 317, 597 RU 486 + anordrin/anordiol, 609 Premenopause, OC use, 229 Progestogen-only contraceptives (POCs), 1, 23 Prostaglandin E2, extraovular, 475 Prostaglandin F2e, intra-amniotic, 475 Radioimmunoassay development, anordrin, 507 Receptor binding, norgestimate, 283 Release characteristics, 3-ketodesogestrel, 251 Replacement hormones + gonadotropin hormone agonist, 427 Reproductive factors, multiple sclerosis incidence, 161 RU 486 + anordrin, 317, 597 RU 486 + anordrin/anordiol, 413, 609 RU 486 + epostane, 499 RU 486 + misoprostol, 295 Safety, POCs, 1 Safety monitor, IUDs, 359 Spermicidal activity, Mollugo pentaphylla, 401 Sterilization, zinc arginine, 107 Subdermal implant, 3-keto-desogestrel, 215, 251 levonorgestrel, 149, 193, 569 nomegestrol acetate, 97 Sulprostone + mifepristone, 123 Tamoxifen, 307 TCu-380A (Ag), 325 Termination of pregnancy, 85, 123, 475, 499 Thermoplastic elastomer condom, barrier efficacy, 559 Trace elements, IUDs, 483
621
622
Contraception
Triphasic OCs, 43, 131, 515 Tripterygium wilfordii, antifertility compounds, 387 Triterpenoid saponin, mollugogenol-A, 401 Tumor necrosis factor alpha, IUDs, 205 Ultrasound, ovarian activity, 583 Uniplant, nomegestrol acetate, 97 Uterine contractility, RU 486 + misoprostol, 295 Vacuum aspiration, 85 Vaginal ring, releasing levonorgestrel, 455 Visiting pill, norethisterone, 527 Zinc arginine, sterilization, 107
- June 1993
Anordiol, synthesis of derivatives, 507 Anordrin + RU 486, 317, 597 Anordrin/anordiol + RU 486, 413, 619 Antifertility effect, human seminal plasma inhibin immunization, 491 tamoxifen, 307 Antioxidant erythrocyte enzyme activities, OC use, 591 Bacille Calmette Guerin, intravasal application, 303 Barrier efficacy, condoms, 559 Biphasic OC, 55, 69 Bleeding patterns, 3-ketodesogestrel, 251 nomegestrol acetate, 97 triphasic OCs, 43 Blood loss, termination of pregnancy, a5 Blood pressure, monophasic OCs, 367 Breast cancer and OC use, 241 Breast cancer prevention, prototype contraceptive, 427 Carbohydrate metabolism, biphasic OC, 55 Cells adherent to IUDs, 205 Chemical male sterilization, 107 Condom choice for contraception, 539 Contraception, older women, 229 Contraceptive choice determinants, 539 Contraceptive potential, tamoxifen, 307 Copper IUDs, 37 Copper release, Cu IUDs, 349 CUT-200, 349, 483 Depot-medroxyprogesterone acetate, 177, 445 Derivatives synthesis, anordiol, 507 Determinants of contraceptive choice, 539 Efficacy, POCs, 1 Endometrial suction, 469 Endometrial trace elements, IUDs, 483 Epididymal injection, zinc arginine, 107 Epostane + RU 486, 499 Erythrocyte enzyme activities, OC use, 591 Ethinyl estradiol + desogestrel, 55, 69, 229, 263, 367, 591 Ethinyl estradiol + gestodene, 263, 367, 583 Ethinyl estradiol + levonorgestrel, 43, 367, 421, 515 Ethinyl estradiol + norethindrone, 43, 131 Ethinyl estradiol + norethisterone acetate, 367, 421 Ethinyl estradiol + norgestrel, 131, 445 Ethinyl estradiol, metabolism, 263 pharmacokinetics, 263 Gemeprost + mefipristone, 75 Genotoxic effect, gossypol acetic acid, 385 Gonadotropin hormone agonist + replacement hormones, 427
620
Contraception
Gossypol acetic acid, genotoxic effect, 385 Gyne T 380, 37 Hormonal parameters, biphasic OC, 55 Human seminal plasma inhibin immunization, 491 :~~~~~~~~fo:r-k~~~~~e~~~~~~~e~~a~~~,i:~:bin, 491 Injectable
contraceptive, depot-medroxyprogesterone acetate, 177, 445 Intrauterine device (IUD), CUT-200, 349, 483 Gyne T 380, 37 levonorgestrel-releasing, 169, 325 Lippes loop, 483 Multiload-375, 325 Nova-T, 325, 349 TCu-380A (Ag), 325 Intravasal Bacille Calmette Guerin, 303 IUD (intrauterine device) IUD choice for contraception, 539 IUD use, safety monitor, 359 IUDs, tumor necrosis factor alpha, 205 3-Keto-desogestrel, subdermal implant, 215, 251 Lactating women, POC use, 23 Latex condoms, barrier efficacy, 559 Levonorgestrel, menstrual blood loss, 455 subdermal implant, 149, 193, 569 Levonorgestrel IUD, 169, 325 Lipid metabolism, biphasic OC, 69 depot-medroxyprogesterone acetate, 177, 445 ethinylestradiol + norgestrel, 445 levonorgestrel, 149 triphasic OCs, 131 Lipid peroxidation, OCs, 421 Lippes loop, 483 Lupron DepotR + Premarin R + Provera R , 427 Male antifertility compounds, Triptergium wilfordii, 387 Male fertility control, 303 Male sterilization, 197 Mechanism of action, POCs, 1 Mefipristone + gemeprost, 85 Mefipristone + sulprostone, 123 Menstrual blood loss, levonorgestrel, 455 Misoprostol + RU 486, 295 Mollugo pentaphylla, spermicidal activity, 401 Monitor, safety of IUD use, 359 Monophasic OCs, 367 Multiload-375, 325 Multiple sclerosis incidence, OC use, 161 reproductive factors, 161 Nomegestrol acetate, subdermal implant, 97 Non-hormonal contraception, endometrial suction, 469
Contraception Norethisterone, 527 Norgestimate, metabolism, 283 receptor binding, 283 Norgestrel POC, 23 Norgestr 1 use, lactating women, 23 Norplant fi, 149, 193, 569 Nova-T, 325, 349 OC use, multiple sclerosis incidence, 161 OC use and breast cancer, 241 OCs (oral contraceptives) Older women, contraception, 229 Ovarian activity, 3-ketodesogestrel, 251 ultrasound, 583 Ovarian function, norethisterone, 527 Performance, levonorgestrel-releasing IUD, 169 Pharmacokinetics, ethinyl estradiol, 263 Pill choice for contraception, 539 Pill-free interval, blood pressure, 367 POC use, lactating women, 23 POCs (progestogen-only contraceptives) Postcoital non-hormonal contraception, 469 Postcoital use, anordrin/anordiol + RU 486, 413 Pregnancy termination, RU 486 + anordrin, 317, 597 RU 486 + anordrin/anordiol, 609 Premenopause, OC use, 229 Progestogen-only contraceptives (POCs), 1, 23 Prostaglandin E2, extraovular, 475 Prostaglandin F2e, intra-amniotic, 475 Radioimmunoassay development, anordrin, 507 Receptor binding, norgestimate, 283 Release characteristics, 3-ketodesogestrel, 251 Replacement hormones + gonadotropin hormone agonist, 427 Reproductive factors, multiple sclerosis incidence, 161 RU 486 + anordrin, 317, 597 RU 486 + anordrin/anordiol, 413, 609 RU 486 + epostane, 499 RU 486 + misoprostol, 295 Safety, POCs, 1 Safety monitor, IUDs, 359 Spermicidal activity, Mollugo pentaphylla, 401 Sterilization, zinc arginine, 107 Subdermal implant, 3-keto-desogestrel, 215, 251 levonorgestrel, 149, 193, 569 nomegestrol acetate, 97 Sulprostone + mifepristone, 123 Tamoxifen, 307 TCu-380A (Ag), 325 Termination of pregnancy, 85, 123, 475, 499 Thermoplastic elastomer condom, barrier efficacy, 559 Trace elements, IUDs, 483
621
622
Contraception
Triphasic OCs, 43, 131, 515 Tripterygium wilfordii, antifertility compounds, 387 Triterpenoid saponin, mollugogenol-A, 401 Tumor necrosis factor alpha, IUDs, 205 Ultrasound, ovarian activity, 583 Uniplant, nomegestrol acetate, 97 Uterine contractility, RU 486 + misoprostol, 295 Vacuum aspiration, 85 Vaginal ring, releasing levonorgestrel, 455 Visiting pill, norethisterone, 527 Zinc arginine, sterilization, 107